Anticoccidial Drugs Market

Anticoccidial Drugs Market Size (2022 to 2027)

The global anticoccidial drugs market is expected to have a growth rate of 3.61% CAGR from 2022 to 2027. As a result, the market is anticipated to grow by USD 1632.99 Million by 2027. 

Coccidian protozoa cause coccidiosis. It is a parasitic disease in the intestinal tract of the animal. The disease spreads from one animal to another by contact with infected tissue or feces. Although most animals are asymptomatic in the spread of this infection, immuno-compromised animals may suffer from severity and death. Therefore, anticoccidial drugs are manufactured with hygienic measures to prevent or control coccidiosis. Coccidiosis is a disease that damages mucosal and submucosal tissues in the intestinal tract of animals and birds.

A few of the key findings from the report:

• Based on the Drug type, the ionophore anticoccidials segment had the largest market share of the global anticoccidial drugs market in 2021.
• The North American anticoccidial drugs market dominated the market in 2021. The market in this region was valued at USD 451.70 million in 2021.
• The Asia-Pacific anticoccidial drugs market is anticipated to grow at a CAGR of 5.49% from 2022 to 2027.
• The European anticoccidial drugs market is estimated to grow by USD 472.75 million by 2027.

Impact of COVID-19 on the global anticoccidial drugs market:

The disease has spread to almost every country globally since the COVID-19 virus outbreak in December 2019, prompting the World Health Organization to declare it a public health emergency. Coccidiosis is a viral disease caused by a single-cell parasite that can only be seen under a microscope. It affects the intestinal tracts of animals. Weight loss, moderate sporadic to extreme diarrhea, diarrhea containing blood or mucus, dehydration, and decreased breeding are all signs of coccidiosis, one of the most common parasitic diseases in domesticated animals. Growing clinical trials in developing medicines or vaccines for animals to prevent infections propels this market's growth rate to new heights. Anticoccidial drugs are drug preparations used to treat coccidiosis in animals. These are given to animals and birds to stop coccidia from reproducing and destroying protozoa in the intestine. In some countries, the transmission of coronavirus from humans to animals boosts the market's growth rate during these pandemic times. In addition, key strategies and increasing awareness of social distancing and wearing masks among market players are expected to boost demand for anticoccidial drugs during the forecast period.

MARKET DRIVERS:

Y-O-Y growth in the prevalence of coccidiosis and increasing focus on animal health primarily accelerates the global anticoccidial drugs market.

Anticoccidial drugs are the agents used to treat, prevent, and control coccidial infections. However, there is a risk of increased coccidiosis due to environmental factors and others, such as contamination or other issues related to hygienic measures. Hence, there is an alarming demand for newer anticoccidial drugs in the drug market. Increasing the need to prevent the spread of diseases in animals with effective medication and the rise in the consumption rate of meat and poultry products are the primary reasons driving the growth of the global anticoccidial drugs market.

The growing number of veterinary hospitals, rise in the demand to improve the quality of drugs with different techniques, growing disposable income in urban areas, and people's concern towards maintaining a healthy diet are further helping the global anticoccidial drugs market to grow.

Additionally, growing support from the government through investments, the rising demand to increase the production rate of drugs with high quality, and increasing concern towards animals' health conditions further accelerate market growth. Furthermore, the adoption of the latest technology, the launch of valuable products, and the rising number of infectious diseases among animals and birds are expected to fuel the growth opportunities for the global anticoccidial drugs market.

MARKET RESTRAINTS:

However, the lack of skilled persons in manufacturing appropriate drugs with correct dosage forms slowly restricts the global anticoccidial drug market demand. In addition, the availability of other drugs at a lower cost and fluctuations in the prices of final products due to less availability of raw materials are expected to limit the growth of the global anticoccidial drugs market. 

REPORT COVERAGE: 

This research report on the global anticoccidial drugs market has been segmented and sub-segmented based on the drug type, animal type, and region.

Anticoccidial Drugs Market - By Drug Type:

• Antibiotic Anticoccidials
• Ionophore Anticoccidials
• Chemical Derivative Anticoccidials

By drug type, the ionophore anticoccidials segment witnessed the highest global market share in 2021. Increasing research and development institutes to launch various drugs are leveraging the growth.

The antibiotic anticoccidials drug segment is expected to grow at the fastest CAGR during the forecast period. The rise in the scale of research institutes to introduce certain types of drugs at high quality with the latest technology creates a chance for the market to grow extensively. Also, the growing economy in almost every region magnifies the market's demand.  

Anticoccidial Drugs Market - By Animal Type:

• Poultry
• Swine
• Fish
• Cattle
• Companion Animal

Based on Animal Type, the poultry animal segment led the anticoccidial drugs market in 2021. The emergence of the latest techniques in manufacturing drugs is prompting market demand. Also, the rise in coccidiosis incidences, especially in food-producing animals, is surging the need for this market.

Anticoccidial Drugs Market - By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Regionally, the North American anticoccidial drugs market was the most dominating region in the global market in 2021 and was worth USD 393.18 million in 2022. The adoption of advanced manufacturing drug techniques majorly drives this regional market. In addition, launching innovative medicines that favor producing the most top-quality products significantly influences the global anticoccidial drugs market.

The APAC anticoccidial drugs market is forecasted to be growing at a CAGR of 4.3% from 2022 to 2027. The Asia Pacific follows North America in holding the largest share of the global market with the rising population, growing demand for poultry products, and increasing government support through funds. In addition, the market is also fuelled by the increasing scale of the regional pharmaceutical industries.

The European anticoccidial drugs market is predicted to grow at a promising CAGR during the forecast period due to the growing meat consumption rate. The U.K. market is estimated to account for most of the share in the European market during the forecast period.

The Latin American anticoccidial drugs market is projected to grow steadily during the forecast period. Therefore, the MEA anticoccidial drugs market is projected to have a prominent growth rate in the coming years.

COMPETITIVE LANDSCAPE:

Noteworthy companies in the global anticoccidial drugs market profiled in this report are Bayer Health care, Zoetis, Elanco, Merial, Merck Animal Healthcare, Ceva Santé Animale, Virbac, Boehringer Ingelheim Animal Health, Novartis Animal Healthcare, and Smartvet Inc. The global anticoccidial drugs market is highly competitive, and major players have adopted product development strategies, mergers, acquisitions, and partnerships to maximize their market share.

In May 2020, Zoetis showed suckling calves with significant weight gain from implants. It is a considerable increase in weaning weight.

In September 2019, Virbac launched Multimin, which is used for cattle. This Multimin is prescription-only for preventing imbalance or detoxifying the harmful effects of tissue damage affecting cattle performance. This multi-minute is designed to manage during the high call in the dairy of beef cattle and dairies like breeding, calving, and vaccination. Once the injection is done, it reaches the blood and liver, which is very quick, simple, and accurate in improving cattle health.

In October 2019, Ceva Sante Animale agreed with ProBioGen, the manufacturer, to represent a transformation of poultry vaccines with the help of ProBioGen's proprietary AGE1.CR technology. AGE1 is a preserved cell line that is obtained from the duck. This cell line is created as a platform to restore chicken cells to manufacture vaccines related to poultry. In addition, Ceva and ProBioGen have a long track in introducing new veterinary vaccines through additional research and development programs.